Actionable insights straight to your inbox


Jnana Therapeutics Launches With $50 Million Series A

Jnana is targeting the solute carrier (SLC) family of transporters, the cell’s metabolic gates (Image: Indiamart)
Trevnea ($TRVN) is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors,
Last week was a tough one for bulls as the market took a pretty sizable tumble. As a result, looked to the Chicago Board Options Exchange Market Volatility Index (VIX), which is popularly known on